
Mary Kay Koenig, MD, a leader in the management of patients with mitochondrial diseases, delves into the complexities of managing patients with thymidine kinase 2 deficiency (TK2d). In this 1-hour activity, Dr. Koenig shares her insights in the clinical presentation of TK2d through real case studies and offers guidance on overcoming the ‘diagnostic odyssey’ experienced by many patients with mitochondrial disease. She also discusses the clinical criteria for referring patients to specialized mitochondrial treatment centers and explores vital aspects of supportive care. Furthermore, Dr. Koenig also reviews a novel therapy for TK2d currently in clinical trials.
Course Credit:
1 AMA PRA Category 1 CreditTM
Dates:
Opens: 2023-10-24
Closes: 2024-10-24
Target Audience:
The education is developed to support neuromuscular specialists and neurologists, pediatricians, primary care providers, pulmonologists, and other specialists who may evaluate symptoms in patients with TK2d.
Supported by an independent educational grant from UCB Pharma.
Accreditation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Additional Content Planners
Lisa van Devender, PharmD (Medical Writer)No significant relationships to disclose.
Sunali Wadehra, MD (Peer Reviewer)
No significant relationships to disclose.
Annenberg Center for Health Sciences
Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.
All of the financial relationships listed for these individuals have been mitigated.
-
Mary Kay Koenig, MD
Professor and Associate Vice-Chair for Clinical Research
Endowed Chair of Mitochondrial Medicine
Director, Center for the Treatment of Pediatric Neurodegenerative Disease
Co-Director, Tuberous Sclerosis Center
Department of Pediatrics, Division of Child and Adolescent Neurology
University of Texas Health Science Center at Houston
UTHealth McGovern Medical School
Houston, Texas
Presenting Faculty
Downloads
Learning Objectives
- Recognize the most common presenting signs and symptoms of early-onset TK2d
- Recognize the most common presenting signs and symptoms of late-onset TK2d
- Apply recommended diagnostic techniques to confirm or exclude TK2d in patients with high clinical suspicion
- Recall the mechanism of action for the TK2d investigational treatment
Faculty Disclosures
Mary Kay Koenig, MD
Consultant: Marinus Pharmaceuticals, Reneo Pharmaceuticals
Data Monitoring Safety Board: UCB
Speakers Bureau: Jazz Pharmaceuticals